Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
Keyuan Zhang, Xiang Zhang, Yang Xu, Shengli Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Suning Chen, Aining Sun, Yanming Zhang, Depei Wu, Ying Wang
Abstract
Core binding factor acute myeloid leukemia (CBF-AML) features the recurrent chromosomal rearrangements t(8;21)(q22;22) and inv(16)(p13.1q22)/t(16;16)(p13.1;q22), which encode the RUNX1::RUNX1T1 and CBFB::MYH11 fusion genes; CBF-AML is considered chemosensitive and classified within the favorable prognosis group [ 1 ]. Induction chemotherapy with cytarabine/anthracycline-based regimens and high-dose cytarabine (AraC)-based regimens is the standard of care for newly diagnosed (ND) or refractory/relapsed (R/R) CBF-AML, respectively [ 1 , 2 ]. However, some patients are not eligible for these intensive therapies due to poor functional status and severe comorbidities.